Sucrose, trehalose, mannitol and maltose are four of the most commonly utilised carbohydrates for protein stabilisation in drug formulations.
As the demand for parenteral excipients continues to rise, the biopharma industry is considering guidance that would require more extensive analysis of a variety of minor constituents, including metals.
Despite the high-purity of many of these excipients, it is important for manufacturers to have an understanding of non-sugar moiety profiles and how they may vary with raw materials and processing.
In this PR, Pfanstiehl presents results of validated metal analysis performed on its injectable-grade platform excipients. Specifically, multiple lots each of trehalose, sucrose, mannitol, and maltose were tested for levels of V, Cr, Mn, Fe, Ni, Cu, Zn, As, Mo, Ru, Rh, Pd, Cd, Os, Ir, Pt, Hg, and Pb. Observations from the data and proposed next steps are discussed.
Materials and methods
For all assays, the parenteral grade carbohydrates (trehalose, sucrose, mannitol, maltose) used were manufactured by Pfanstiehl. Inductively coupled plasma mass spectrometry (ICP-MS) analysis was performed using a Thermo iCapQ ICP-MS instrument.
Each 320mg sample was diluted in 5% HNO3 and 5% HCl prior to analysis. The peristaltic pump speed was 30rpm. Auto-sampler rinse and wash were set to 90 seconds each. Additional method details can be provided upon request.
The upper limit was set as a harmonised limit based on the lower of the two levels suggested by the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP).
The data illustrates that in all cases, these particular parenteral excipients have exceptionally low levels of the metals tested. In fact, there was only one instance where a result was above the limit of quantitation. In that case, one lot of trehalose had a cadmium (Cd) level of 0.11ppm against a limit of quantitation of 0.05ppm and harmonized limit of 0.25ppm.
Given the very low levels of metals detected by these fully validated test methods, one can conclude that the materials assayed are unlikely to cause any safety concerns with respect to metal contribution.
There is also virtually no risk of these particular excipients failing to pass metal limits proposed by USP, EP and International Conference on Harmonisation (ICH) bodies in the future. This should provide a level of confidence for manufacturers and formulators using these excipients in existing processes and in pipeline development programmes.
The next step will be to try to correlate application data with these and other impurity profiles, and to map their impacts on formulation robustness and stability. At the very least, availability of such data should enable better decisions with respect to sourcing of critical raw materials for a variety of formulation applications, including media optimisation, protein stabilisation for liquid and lyophilised platforms, vaccine stabilisation and cell therapy.